MB-07803
MB-07803 is an orally active second-generation prodrug inhibitor of fructose-1,6-bisphosphatase (FBP1). MB-07803 directly inhibits the rate-limiting enzyme in gluconeogenesis. MB-07803 regulates blood glucose and is used in studies of type 2 diabetes.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 882757-24-6
- Formule: C24H37N4O7PS
- Masse moléculaire:556.61
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
31, 121, 189 nM for human, monkey, and rat, respectively [1] .
In Vitro
Gluconeogenesis refers to the metabolic pathway in which the body converts non-carbohydrate precursors (such as lactate, glycerol, and amino acids) into glucose. It primarily occurs in the liver and kidneys and is crucial for maintaining stable blood glucose levels during fasting. Its overactivity is a significant mechanism in type 2 diabetes. Fructose-1,6-bisphosphatase (FBP1) is a key rate-limiting enzyme in the gluconeogenesis pathway, catalyzing the hydrolysis of fructose-1,6-bisphosphate into fructose-6-phosphate and inorganic phosphate. Expressed in the liver and kidneys, it is an important target for drug development in type 2 diabetes. Inhibiting FBP1 can reduce hepatic glucose output, thereby controlling blood glucose levels.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 882757-24-6
-
Masse moléculaire 556.61
-
Formule C24H37N4O7PS
-
SMILES
O=C(C(C)(C)NP(NC(C)(C)C(OCC)=O)(C1=CC=C(C2=C(C(C(C)(C)C)=O)SC(N)=N2)O1)=O)OCC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)